Brit. med. _J., 1966, 1, 454-456 The term " thrombolytic therapy " refers to the attempted removal of preformed intravascular fibrin occlusions using fibrinolytic agents. Several substances have been described as inducing a fibrinolytic state in the peripheral blood ; however, for only a few of these (namely, the plasminogen activators streptokinase and urokinase) was it proved beyond reasonable doubt that administration resulted in an increase in fibrinolytic activity to the point of dissolving intravascular thrombi. After critical clinical evaluation the overall results with streptokinase-plasmin mixtures were rather disappointing and it was still unclear which of the two agents was responsible for the action.
The purpose of this paper is to demonstrate that where a standard dosage scheme which has been proved to induce thrombolysis can be used for streptokinase administration, cumbersome laboratory controls become non-essential, thus making clinical trials accessible to a larger group of investigators.
Experimental Data Leading to the Adoption of a
Standard Dosage Scheme
Search for a Standard Initial Dose of Streptokinase
A prerequisite for the induction of a fibrinolytic state in man is that the lytic activity produced overcomes the endogenous inhibitors present in the circulating blood. If therapeutic thrombolysis is to be induced with streptokinase (S.K.), the activity of antibodies and inhibitors to this enzyme has to be neutralized. The purpose of the initial loading dose of S.K. is therefore to neutralize these antagonists by the infusion of an amount of S.K. equivalent to the measured amount of circulating inhibitor.
Various titration methods for computing this dose (commonly termed " titrated initial dose " (T.I.D.)) have been developed and do not differ substantially (Deutsch and Fischer, 1960; Fischbacher, 1961 ; Nilsson and Olow, 1962 ; Amery et al., 1963) .
Based on published results of eight investigators Deutsch and Fischer, 1960; Deutsch et al., 1961 Stacher and Boechnel, 1961 ; Nilsson and Olow, 1962 ; Olow, 1962 Olow, , 1963 McNicol et al., 1963 ; Helle, 1963 ; Winckelmann and Heimeyer, 1964 ; Abastado, 1964) it was found that the titrated initial dose may vary fromn 25,000 units of S.K. in one individual to 1,500,000 units in another. The average initial doses in these eight series ranged between 152,000 and 359,000 units S.K. The mean initial dose for the whole group of 99 subjects was found to be 294,000 units S.K. Johnson et al. (1957) (Vermylen et al., 1963) . The value of this test for evaluating the coagulation defect during S.K. administrations has been discussed previously (Verstraete et al., 1964a 
Comments
In previous studies evidence has been presented that in the presence of a low concentration of circulating plasminogen the administration of a large amount of S.K. will result in an important level of activator activity without measurable free plasmin activity (Johnson and McCarty, 1959) . The standard scheme used in the latest group of our clinical experiments aims at obtaining a high level of circulating activator activity which would activate plasminogen trapped in the fibrin web (Alkjaersig et al., 1959) . At the beginning of thrombolytic therapy it has not been possible to avoid an initial phase of hyperplasminaemia with consequent fibrinogen breakdown and the appearance of polymerization inhibitors (Verstraete et al., 1964b) . However, after [24] [25] [26] [27] [28] [29] [30] [31] [32] An important advantage-of a standard administration scheme of S.K. is that the laboratory control is greatly simplified and is not even essential. This burden of control, and the lack of good assay systems, have in the past been major problems in fibrinolytic therapy. The required facilities for plasminogen determinations and other assays are not necessarily present in smaller hospitals and the accuracy of laboratory assessments only occasionally performed may be questioned.
Using intense and prolonged S.K. administration, properly conducted according to the criteria mentioned above, pulsative blood flow was restored in 12 of the 15 treated cases. In nine cases where the pulsative flow was restored, arteriographic series were taken before and after the S.K. administration. In all of them clearing of the main artery was found.
It was hoped that rapid restoration of blood-flow would prevent irreversible tissue necrosis. However, in some cases, though pulsative blood flow was restored, amputation of at least some part of the involved extremity was necessary. Therefore any modification of S.K. treatment which restores the blood-flow more rapidly could be of crucial importance. This might be a further reason for presenting a standard administration scheme for S.K., rather than a scheme varying according to the patient, where the necessary laboratory controls would delay the start of S.K. administration.
We are aware that this new administration scheme may result in very widespread use of this material in hospitals. At present, however, only a high incidence of thrombolysis in vivo by streptokinase administration has been proved. Comparative studies of the mortality rate, limb amputation rate, and the incidence of recurrence with S.K. therapy and other forms of treatment of recent peripheral arterial occlusions are not available at this time. This information should be available before the widespread use of S.K. can be justified.
Summary
The feasibility and efficiency of a standard administration scheme have been explored, using experience gained from previous experiments and clinical trials with streptokinase (S.K.) as a thrombolytic agent in man. With a set initial dose of 1,250,000 U. S.K. administered intra-arterially or intravenously in less than 30 minutes and a maintenance dose of 100,000 U. S.K./hour for three days, restoration of arterial blood-flow was obtained in 12 of 15 arterial occlusions.
anginal pain is a poor criterion of the effect of a drug in improving myocardial ischaemia (Russek, 1955 ; Sandler et al., 1963) . This is obviously true for drugs acting on pathways of pain transmission. Alcohol, sedatives, tranquillizers, and monoamine oxidase inhibitors may favourably influence angina without electrocardiographic improvement (Russek et al., 1950 (Russek et al., , 1955 .
On the other hand, the validity of the electrocardiographic method in identifying effective agents, such as glyceryl trinitrate, is based on the observation that such drugs increase the exercise tolerance (Sandler et al., 1963, Russek and Howard, 1964) . Angina and electrocardiographic changes may both reflect ischaemia in a minute area of the myocardium. The choice of method for evaluating less potent long-acting nitrates depends, therefore, on which method is most sensitive and reproducible when applied on a population with angina pectoris.
Most patients with coronary insufficiency believe that they are able to state quite exactly the onset of pain, and often develop pain in their daily life after the same amount of exercise.
Whether this reflects coronary insufficiency at identical work loads or is due rather to a psychological reaction to the situation when pain is known to occur has not been settled. By using a Master two-step technique (Sandler et al., 1963) the patients may count the number of circuits accomplished. In the present study exercise was therefore performed on a bicycle ergometer. The ordinary controlled double-blind technique was modified in so far that the patients were told that the drugs had different potency and were likely to delay the onset of pain differently. This was done in order to minimize the placebo effect. The order of administration was of course kept secret. On three consecutive days one hour before exercise a placebo tablet or one of two long-acting nitrates (pentaerythritol tetranitrate and methylpropylpropandioldinitrate) was administered according to a permutation scheme (Kiil, 1960) . Methylpropylpropandioldinitrate is synthesized by Apothekernes Laboratorium for Specialpraeparater, Oslo, and marketed as Nitral.
